Alizin 30 mg/ml Solution for Injection

Authorised

- Aglepristone

Product identification

Medicine name:
Alizin 30 mg/ml Solution for Injection
Alizin vet. 30 mg/ml injeksjonsvæske, oppløsning

Active substance:
Aglepristone

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Aglepristone
30.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QG03XB90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Norway

Package description:
Vial (glass, type II) of 5 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation: - box of 1 vial of 5ml
Vial (glass, type II) of 10 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation: - box of 1 vial of 10ml.
Vial (glass, type II) of 30 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation: - box of 1 vial of 30ml.
Vials (glass, type II) of 10 ml for injectable preparations, with bromobutyl stoppers and aluminum caps. Presentation: - box of 10 vials of 10ml.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
27/07/2004

Manufacturing sites for batch release:
VIRBAC

Responsible authority:
Norwegian Medicines Agency

Authorisation number:
03-2047

Date of authorisation status change:
26/11/2008

Reference member state:
Ireland

Procedure number:
IE/V/0500/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
